

Company Registration No. SC432684 (Scotland)

DEANS PHARMACEUTICALS LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2018
PAGES FOR FILING WITH REGISTRAR

DEANS PHARMACEUTICALS LTD

CONTENTS

	Page
Balance sheet	1 - 2
Notes to the financial statements	3 - 8

DEANS PHARMACEUTICALS LTD

BALANCE SHEET

AS AT 30 NOVEMBER 2018

		2018		2017	
	Notes	£	£	£	£
Fixed assets					
Intangible assets	3		910,000		975,000
Tangible assets	4		211,451		264,916
Investments	5		4,376,869		-
			<u>5,498,320</u>		<u>1,239,916</u>
Current assets					
Stocks		115,381		101,012	
Debtors	6	557,537		473,680	
Cash at bank and in hand		180,962		209,823	
		<u>853,880</u>		<u>784,515</u>	
Creditors: amounts falling due within one year	7	(944,825)		(844,706)	
Net current liabilities			<u>(90,945)</u>		<u>(60,191)</u>
Total assets less current liabilities			5,407,375		1,179,725
Creditors: amounts falling due after more than one year	8		(4,462,919)		(434,944)
Provisions for liabilities			<u>(14,641)</u>		<u>(44,623)</u>
Net assets			<u>929,815</u>		<u>700,158</u>
Capital and reserves					
Called up share capital	9		2		2
Profit and loss reserves			929,813		700,156
Total equity			<u>929,815</u>		<u>700,158</u>

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.

For the financial year ended 30 November 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

DEANS PHARMACEUTICALS LTD

BALANCE SHEET (CONTINUED)

AS AT 30 NOVEMBER 2018

The financial statements were approved by the board of directors and authorised for issue on 1 August 2019 and are signed on its behalf by:

Mr Arif Hanif
Director

Mr John Connolly
Director

Company Registration No. SC432684

DEANS PHARMACEUTICALS LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 NOVEMBER 2018

1 Accounting policies

Company information

Deans Pharmaceuticals Ltd is a private company limited by shares incorporated in Scotland. The registered office is 1st Floor, 133 Finnieston Street, Glasgow, G3 8HB.

1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies. The principal accounting policies adopted are set out below.

1.2 Turnover

Turnover comprises revenue recognised by the company in respect of pharmaceutical services provided during the year, exclusive of Value Added Tax and trade discounts.

1.3 Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

1.4 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Shop development	5% straight line
Fixtures, fittings & equipment	16.67% - 20% straight line
Motor vehicles	25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5 Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

DEANS PHARMACEUTICALS LTD

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 NOVEMBER 2018

1 Accounting policies

(Continued)

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

1.6 Stocks

Stocks are valued at the lower of cost and net realisable value.

1.7 Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts.

1.8 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.9 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.10 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

DEANS PHARMACEUTICALS LTD

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 NOVEMBER 2018

1 Accounting policies

(Continued)

1.11 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12 Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

Government grants relating to turnover are recognised as income over the periods when the related costs are incurred. Grants relating to an asset are recognised in income systematically over the asset's expected useful life. If part of such a grant is deferred it is recognised as deferred income rather than being deducted from the asset's carrying amount.

2 Employees

The average monthly number of persons (including directors) employed by the company during the year was 19 (2017 - 19).

3 Intangible fixed assets

	Goodwill £
Cost	
At 1 December 2017 and 30 November 2018	1,300,000
Amortisation and impairment	
At 1 December 2017	325,000
Amortisation charged for the year	65,000
At 30 November 2018	390,000
Carrying amount	
At 30 November 2018	910,000
At 30 November 2017	975,000

DEANS PHARMACEUTICALS LTD

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 NOVEMBER 2018

4 Tangible fixed assets

	Shop development	Fixtures, fittings & equipment	Motor vehicles	Total
	£	£	£	£
Cost				
At 1 December 2017 and 30 November 2018	100,857	226,283	12,680	339,820
Depreciation and impairment				
At 1 December 2017	24,503	48,021	2,375	74,899
Depreciation charged in the year	5,043	45,257	3,170	53,470
At 30 November 2018	29,546	93,278	5,545	128,369
Carrying amount				
At 30 November 2018	71,311	133,005	7,135	211,451
At 30 November 2017	76,351	178,262	10,303	264,916

5 Fixed asset investments

	2018 £	2017 £
Investments	4,376,869	-

Movements in fixed asset investments

	Shares in group undertakings £
Cost or valuation	
At 1 December 2017	-
Additions	4,376,869
At 30 November 2018	4,376,869
Carrying amount	
At 30 November 2018	4,376,869
At 30 November 2017	-

DEANS PHARMACEUTICALS LTD

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 NOVEMBER 2018

6 Debtors	2018	2017
	£	£
Amounts falling due within one year:		
Trade debtors	467,863	404,153
Other debtors	89,674	69,527
	<u>557,537</u>	<u>473,680</u>
7 Creditors: amounts falling due within one year	2018	2017
	£	£
Bank loans and overdrafts	231,691	25,139
Trade creditors	266,341	269,889
Corporation tax	69,843	26,417
Other taxation and social security	4,573	5,673
Other creditors	372,377	517,588
	<u>944,825</u>	<u>844,706</u>
Bank loans are secured.		
8 Creditors: amounts falling due after more than one year	2018	2017
	£	£
Bank loans and overdrafts	4,418,919	361,611
Other creditors	44,000	73,333
	<u>4,462,919</u>	<u>434,944</u>
Bank loans are secured.		
Amounts included above which fall due after five years are as follows:		
Payable by instalments	<u>3,492,154</u>	<u>256,667</u>
9 Called up share capital	2018	2017
	£	£
Ordinary share capital		
Issued and fully paid		
2 Ordinary shares of £1 each	<u>2</u>	<u>2</u>

DEANS PHARMACEUTICALS LTD

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 NOVEMBER 2018

10 Related party transactions

Transactions with related parties

During the year the company entered into the following transactions with related parties:

Mr A Hanif and Mr J Connolly are also directors and shareholders of Deans Healthcare Ltd. Included within Other creditors is a balance of £165,513 (2017: £334,749) due to Deans Healthcare Ltd. This loan is interest free and has no fixed terms for repayment.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.